Better Artificial Intelligence Stock: Aehr Test Systems vs. Super Micro Computer

Super Micro Computer is presented as the preferred AI infrastructure investment after FY2026 revenue rose 77.8% to $39.1 billion and net income reached $2.2 billion, while its 9.9x forward P/E and 0.6x P/S are far below Aehr Test Systems' 117.7x and 55.5x, respectively. Aehr's FY2026 revenue fell 15.2% to $50.0 million, producing a $7.1 million net loss and negative $5.4 million free cash flow, despite a debt-free balance sheet. Super Micro's investment case is tempered by negative $7.0 billion free cash flow, customer concentration, accounting-related litigation, and alleged export-control violations involving former employees.

Analysis

SMCI’s apparent valuation discount should be read as a risk-adjusted financing and governance discount, not simply a growth mispricing. Its cash conversion is the critical variable: rapid rack deployment requires inventory, receivables, and supplier commitments to expand ahead of revenue recognition, so a sustained working-capital drain could force lower-margin financing or constrain buybacks despite reported earnings growth. Over the next 1-3 months, the relevant catalyst is evidence that receivable days and inventory normalize while gross margin holds; that combination would support multiple expansion versus AI infrastructure peers.

AEHR has the opposite setup: its balance sheet provides runway, but does not validate an equity valuation that assumes a sharp recovery in utilization and customer diversification. Wafer-level burn-in is a technically valuable niche, yet equipment demand is inherently lumpy and a concentrated customer base makes a single program delay disproportionately destructive to revenue, gross-margin absorption, and consensus estimates. The second-order beneficiary of delayed SiC/automotive qualification spending would be incumbent test platforms and diversified semiconductor-equipment vendors, while AEHR remains exposed to a narrow set of design-win cycles.

Consensus is likely too focused on SMCI’s revenue growth versus AEHR’s weak fundamentals, and insufficiently focused on the durability of SMCI’s export-control and accounting overhang. A favorable resolution or clean filing cycle can rerate SMCI quickly, but any further compliance issue would impair customer willingness to commit to large deployments, turning its working-capital model from an execution issue into a liquidity issue. This is therefore a better relative-value than outright-AI-beta expression: SMCI has measurable near-term operational proof points, whereas AEHR needs a multi-quarter demand inflection to justify its premium.

Key Decisions for Investors

• Initiate a 3-6 month pair: long SMCI / short AEHR, sized beta-neutral. Thesis is multiple compression in AEHR and normalization of SMCI’s governance discount; target a 20-30% relative move. Exit if SMCI reports worsening receivable or inventory intensity alongside gross-margin deterioration, or if AEHR announces a material multi-customer order recovery.
• For a lower-volatility expression, buy SMCI only after the next filing/earnings release confirms timely reporting and stable-to-improving operating cash conversion. Use a 10-12% downside stop from entry; the upside case is a rerating if compliance uncertainty recedes without an AI-server demand slowdown.
• Avoid adding AEHR on balance-sheet strength alone. Revisit only if backlog/order visibility supports sequential revenue growth and management demonstrates that new customers reduce concentration; absent that evidence, a high-sales multiple leaves substantial downside on another guide-down.
• Monitor NVDA platform availability and AI-server lead times as the key read-through for SMCI, but treat them as insufficient on their own: SMCI must convert shipments into cash. A broad AI hardware demand slowdown or renewed China export restrictions would invalidate the long leg and favor reducing gross exposure immediately.